PURPOSE: To evaluate outcome after fractionated stereotactic radiotherapy (FSRT) and concomitant daily temozolomide (TMZ) in patients with recurrent gliomas. MATERIALS AND METHODS: Twenty-five patients with recurrent or progressive gliomas were treated with FSRT in combination with TMZ at the Department of Radiation Oncology, University of Heidelberg. Histologic classification at primary diagnosis included low-grade astrocytoma in 7 patients (28%), grade III gliomas in 10 patients (40%) and glioblastoma in 8 patients (32%). All patients had undergone at least one neurosurgical resection, which was complete in 5 patients (20%), subtotal in 13 patients (52%) and a biopsy only in 7 patients (28%). Nineteen patients (76%) had undergone neurosurgical resection for tumor recurrence. All patients had received radiation therapy with a median dose of 60 Gy. The median time interval between primary RT and re-irradiation was 36 months. Using FSRT, we applied a median total dose of 36 Gy in a median fractionation of 5 x 2 Gy/week. Chemotherapy with TMZ was applied in a median dose of 50 mg/m(2). RESULTS: Median overall survival was 59 months. Median survival from re-irradiation was 8 months. Actuarial survival rates at 6 and 12 months were 81% and 25%. Median PFS was 5 months; actuarial PFS rates at 6 and 12 months were 48% and 16%. Treatment could be completed in all patients as scheduled without interruptions >3 days. No severe treatment-related side effects could be observed. CONCLUSION: Re-irradiation and TMZ is safe and effective in a subgroup of patients with recurrent gliomas. Further evaluation of radiochemotherapy regimens for recurrent or progressive gliomas is warranted.
PURPOSE: To evaluate outcome after fractionated stereotactic radiotherapy (FSRT) and concomitant daily temozolomide (TMZ) in patients with recurrent gliomas. MATERIALS AND METHODS: Twenty-five patients with recurrent or progressive gliomas were treated with FSRT in combination with TMZ at the Department of Radiation Oncology, University of Heidelberg. Histologic classification at primary diagnosis included low-grade astrocytoma in 7 patients (28%), grade III gliomas in 10 patients (40%) and glioblastoma in 8 patients (32%). All patients had undergone at least one neurosurgical resection, which was complete in 5 patients (20%), subtotal in 13 patients (52%) and a biopsy only in 7 patients (28%). Nineteen patients (76%) had undergone neurosurgical resection for tumor recurrence. All patients had received radiation therapy with a median dose of 60 Gy. The median time interval between primary RT and re-irradiation was 36 months. Using FSRT, we applied a median total dose of 36 Gy in a median fractionation of 5 x 2 Gy/week. Chemotherapy with TMZ was applied in a median dose of 50 mg/m(2). RESULTS: Median overall survival was 59 months. Median survival from re-irradiation was 8 months. Actuarial survival rates at 6 and 12 months were 81% and 25%. Median PFS was 5 months; actuarial PFS rates at 6 and 12 months were 48% and 16%. Treatment could be completed in all patients as scheduled without interruptions >3 days. No severe treatment-related side effects could be observed. CONCLUSION: Re-irradiation and TMZ is safe and effective in a subgroup of patients with recurrent gliomas. Further evaluation of radiochemotherapy regimens for recurrent or progressive gliomas is warranted.
Authors: Ilwoo Park; Gregory Tamai; Michael C Lee; Cynthia F Chuang; Susan M Chang; Mitchel S Berger; Sarah J Nelson; Andrea Pirzkall Journal: Int J Radiat Oncol Biol Phys Date: 2007-05-21 Impact factor: 7.038
Authors: Daniela Schulz-Ertner; Claudia Frank; Klaus K Herfarth; Bernhard Rhein; Michael Wannenmacher; Jürgen Debus Journal: Int J Radiat Oncol Biol Phys Date: 2002-11-15 Impact factor: 7.038
Authors: Stephanie E Combs; Sybille Gutwein; Daniela Schulz-Ertner; Michael van Kampen; Christoph Thilmann; Lutz Edler; Michael M Wannenmacher; Jürgen Debus Journal: Strahlenther Onkol Date: 2005-06 Impact factor: 3.621
Authors: W K Yung; M D Prados; R Yaya-Tur; S S Rosenfeld; M Brada; H S Friedman; R Albright; J Olson; S M Chang; A M O'Neill; A H Friedman; J Bruner; N Yue; M Dugan; S Zaknoen; V A Levin Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Shannon E Fogh; David W Andrews; Jon Glass; Walter Curran; Charles Glass; Colin Champ; James J Evans; Terry Hyslop; Edward Pequignot; Beverly Downes; Eileen Comber; Mitchell Maltenfort; Adam P Dicker; Maria Werner-Wasik Journal: J Clin Oncol Date: 2010-05-17 Impact factor: 44.544
Authors: G Minniti; V Armosini; M Salvati; G Lanzetta; P Caporello; M Mei; M F Osti; R Enrici Maurizi Journal: J Neurooncol Date: 2010-11-05 Impact factor: 4.130
Authors: A Baehr; D Trog; M Oertel; S Welsch; K Kröger; O Grauer; U Haverkamp; H T Eich Journal: Strahlenther Onkol Date: 2020-02-03 Impact factor: 3.621
Authors: A Zygogianni; M Protopapa; A Kougioumtzopoulou; F Simopoulou; S Nikoloudi; V Kouloulias Journal: Clin Transl Oncol Date: 2018-01-15 Impact factor: 3.405
Authors: Jennifer Clarke; Elizabeth Neil; Robert Terziev; Philip Gutin; Igor Barani; Thomas Kaley; Andrew B Lassman; Timothy A Chan; Josh Yamada; Lisa DeAngelis; Ase Ballangrud; Robert Young; Katherine S Panageas; Kathryn Beal; Antonio Omuro Journal: Int J Radiat Oncol Biol Phys Date: 2017-06-30 Impact factor: 7.038
Authors: Joshua T McKenzie; Jess N Guarnaschelli; Achala S Vagal; Ronald E Warnick; John C Breneman Journal: J Neurooncol Date: 2013-04-16 Impact factor: 4.130